Jim Cramer labels Vertex Pharmaceuticals a buy, citing its impactful mission. Analysts project a 22.33% upside for Vertex stock, despite current bearish momentum. Memorial Day Special: Access your ...

Despite commanding over 90% of its revenue from its cystic fibrosis drug franchise, Vertex has been unable to fend off investor skepticism. In 2024, the company made waves with CASGEVY, the first gene ...

Want an edge in trading? Follow the Big Money. What’s Big Money? Said simply, it’s when a stock rises due to institutional demand. Top stocks tend to attract savvy investors. You see, fund managers ...

Deal Values Each Alpine Share at a 38% Premium to Wednesday’s Closing Price Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Vertex shares ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total ...

Vertex, Inc. engages in the provision of tax compliance software solutions. The firm offers comprehensive solutions that automate end-to-end indirect tax processes for enterprises and mid-market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.